These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Pharmacological characterization of 2NTX-99 [4-methoxy-N1-(4-trans-nitrooxycyclohexyl)-N3-(3-pyridinylmethyl)-1,3-benzenedicarboxamide], a potential antiatherothrombotic agent with antithromboxane and nitric oxide donor activity in platelet and vascular preparations. Buccellati C; Sala A; Rossoni G; Capra V; Rovati GE; Di Gennaro A; Folco G; Colli S; Casagrande C J Pharmacol Exp Ther; 2006 May; 317(2):830-7. PubMed ID: 16399881 [TBL] [Abstract][Full Text] [Related]
6. A paradox of thrombogenesis by streptokinase and its prevention by iloprost and camonagrel. Korbut R; Gryglewski RJ Methods Find Exp Clin Pharmacol; 1996 Apr; 18(3):167-74. PubMed ID: 8738067 [TBL] [Abstract][Full Text] [Related]
7. Thrombolysis by thienopyridines and their congeners. Gryglewski RJ; Dupin JP; Uracz W; Swiês J; Madej J; Hou G; Gravier D; Casadebaig F J Physiol Pharmacol; 2000 Dec; 51(4 Pt 1):683-93. PubMed ID: 11192941 [TBL] [Abstract][Full Text] [Related]
8. [Effects of 3-n-butylphthalide on thrombosis formation and platelet function in rats]. Xu HL; Feng YP Yao Xue Xue Bao; 2001 May; 36(5):329-33. PubMed ID: 12584852 [TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N'-[2-(4'-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. Hanson J; Rolin S; Reynaud D; Qiao N; Kelley LP; Reid HM; Valentin F; Tippins J; Kinsella BT; Masereel B; Pace-Asciak C; Pirotte B; Dogné JM J Pharmacol Exp Ther; 2005 Apr; 313(1):293-301. PubMed ID: 15626721 [TBL] [Abstract][Full Text] [Related]
10. Function of tissue-type plasminogen activator releaser on vascular endothelial cells and thrombolysis in vivo. Ueshima S; Matsuno H; Hayashi M; Horibuchi K; Okada K; Fukao H; Uematsu T; Matsuo O Thromb Haemost; 2002 Jun; 87(6):1069-74. PubMed ID: 12083488 [TBL] [Abstract][Full Text] [Related]
11. Endothelial cells play an important role in the antiaggregatory effect of nitric oxide. Klinge JM; Topf HG; Trusen B; Rauh M; Rascher W; Dötsch J Crit Care Med; 2003 Jul; 31(7):2010-4. PubMed ID: 12847397 [TBL] [Abstract][Full Text] [Related]
12. Anticoagulant and antithrombotic activity of a new peptide pENW (pGlu-Asn-Trp). Xiong J; Fang W; Fang W; Bai L; Huo J; Kong Y; Yunman L J Pharm Pharmacol; 2009 Jan; 61(1):89-94. PubMed ID: 19126301 [TBL] [Abstract][Full Text] [Related]
13. Nitric oxide complements prostacyclin in the regulation of endothelial thromboresistance under flow conditions. Korbut R; Ocetkiewicz A; Gryglewski RJ Methods Find Exp Clin Pharmacol; 1993 Apr; 15(3):179-81. PubMed ID: 8332034 [TBL] [Abstract][Full Text] [Related]
14. Loss of anti-aggregatory effects of aortic valve tissue in patients with aortic stenosis. Chirkov YY; Mishra K; Chandy S; Holmes AS; Kanna R; Horowitz JD J Heart Valve Dis; 2006 Jan; 15(1):28-33. PubMed ID: 16480009 [TBL] [Abstract][Full Text] [Related]
15. Endothelial nitric oxide, prostacyclin (PGI2) and tissue plasminogen activator (t-PA): alliance or neutrality? Gryglewski RJ Pol J Pharmacol; 1995; 47(5):467-72. PubMed ID: 8868142 [TBL] [Abstract][Full Text] [Related]
16. On the mechanism of thrombolytic action of thromboxane synthetase inhibitors. Korbut R; Dembińska-Kieć A; Swies J; Zmuda A; Gryglewski RJ Thromb Haemost; 1987 Oct; 58(3):827-30. PubMed ID: 3324381 [TBL] [Abstract][Full Text] [Related]
17. Involvement of nitric oxide in the mediation of the hypotensive action of the essential oil of Mentha x villosa in normotensive conscious rats. Lahlou S; Magalhães PJ; Carneiro-Leão RF; Leal-Cardoso JH Planta Med; 2002 Aug; 68(8):694-9. PubMed ID: 12221590 [TBL] [Abstract][Full Text] [Related]
18. Comparison of antiplatelet effects of two nitric oxide-donating agents, FR146801 and FK409. Hirasawa Y; Kato Y; Fukuyama S; Ohno M; Nishino S; Kato M; Kita Y Thromb Haemost; 1998 Mar; 79(3):620-4. PubMed ID: 9531052 [TBL] [Abstract][Full Text] [Related]
19. FK419, a nonpeptide platelet glycoprotein IIb/IIIa antagonist, ameliorates brain infarction associated with thrombotic focal cerebral ischemia in monkeys: comparison with tissue plasminogen activator. Maeda M; Moriguchi A; Mihara K; Aoki T; Takamatsu H; Matsuoka N; Mutoh S; Goto T J Cereb Blood Flow Metab; 2005 Jan; 25(1):108-18. PubMed ID: 15678117 [TBL] [Abstract][Full Text] [Related]
20. Antiplatelet and antithrombotic activity of SL65.0472, a mixed 5-HT1B/5-HT2A receptor antagonist. Berry CN; Lorrain J; Lochot S; Delahaye M; Lalé A; Savi P; Lechaire I; Ferrari P; Bernat A; Schaeffer P; Janiak P; Duval N; Grosset A; Herbert JM; O'Connor SE Thromb Haemost; 2001 Mar; 85(3):521-8. PubMed ID: 11307825 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]